The Hyderabad-based biotechnology company Biotech has been in the news since they manufactured the Covaxin and vaccinated citizens in phase 1 of the vaccination drive.
This company is now looking to make a big move by engaging in talks with global pharma giants in manufacturing the vaccine and increase the supply and ensure this vaccine reaches every country. This decision to ramp up discussion with global giants has come after the company cracked a big deal with Indian Immunologicals to help manufacture the vaccine to increase stock as multiple states in India are staring at a vaccine shortage, with Telangana stopping all their phases of the drive due to the same.
Their current talks with Ocugen in the US and other European giants and a French company are keen on manufacturing Covaxin in India, reducing transportation time by a great deal. Apart from their current discussion, Bharat Biotech expects to crack few more deals and will work towards manufacturing 700 million vaccine doses per year. The recent deal with ILL (Indian Immunologicals Limited) has a few million doses by July to meet the demand in various states and increase their manufacturing speed by 10million by December 2021.
Apart from this, the central government has signed two agreements, one with the Maharashtrian pharmaceutical group to produce an additional 20 million doses and the other with Bharat Immunologicals and Biologicals limited to manufacture 15million dosages. All the current deals and discussions with national and international pharma giants are a measure to prevent the vaccine shortages that few states face and ensure this does not happen when the entire country decides to speed up the vaccination drive.